<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9940625</article-id>
    <article-id pub-id-type="pmid">36805623</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btad085</article-id>
    <article-id pub-id-type="publisher-id">btad085</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Paper</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Data and Text Mining</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Multimodal representation learning for predicting molecule–disease relations</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5067-2647</contrib-id>
        <name>
          <surname>Wen</surname>
          <given-names>Jun</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, Harvard Medical School</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
        <aff><institution>VA Boston Healthcare System</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Xiang</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, Harvard Medical School</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rush</surname>
          <given-names>Everett</given-names>
        </name>
        <aff><institution>Department of Energy, Oak Ridge National Laboratory</institution>, Oak Ridge, TN 37831, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Panickan</surname>
          <given-names>Vidul A</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, Harvard Medical School</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
        <aff><institution>VA Boston Healthcare System</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Xingyu</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, Harvard Medical School</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Cai</surname>
          <given-names>Tianrun</given-names>
        </name>
        <aff><institution>VA Boston Healthcare System</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
        <aff><institution>Mass General Brigham</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhou</surname>
          <given-names>Doudou</given-names>
        </name>
        <aff><institution>Department of Statistics, University of California</institution>, Davis, CA 95616, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ho</surname>
          <given-names>Yuk-Lam</given-names>
        </name>
        <aff><institution>VA Boston Healthcare System</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Costa</surname>
          <given-names>Lauren</given-names>
        </name>
        <aff><institution>VA Boston Healthcare System</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Begoli</surname>
          <given-names>Edmon</given-names>
        </name>
        <aff><institution>Department of Energy, Oak Ridge National Laboratory</institution>, Oak Ridge, TN 37831, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hong</surname>
          <given-names>Chuan</given-names>
        </name>
        <aff><institution>VA Boston Healthcare System</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
        <aff><institution>Department of Biostatistics and Bioinformatics, Duke University</institution>, Durham, NC 27708, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gaziano</surname>
          <given-names>J Michael</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, Harvard Medical School</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
        <aff><institution>VA Boston Healthcare System</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
        <aff><institution>Brigham and Women’s Hospital</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1727-7076</contrib-id>
        <name>
          <surname>Cho</surname>
          <given-names>Kelly</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, Harvard Medical School</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
        <aff><institution>VA Boston Healthcare System</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
        <aff><institution>Brigham and Women’s Hospital</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lu</surname>
          <given-names>Junwei</given-names>
        </name>
        <aff><institution>VA Boston Healthcare System</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
        <aff><institution>Department of Biostatistics, Harvard T.H. Chan School of Public Health</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liao</surname>
          <given-names>Katherine P</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, Harvard Medical School</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
        <aff><institution>VA Boston Healthcare System</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
        <aff><institution>Department of Biostatistics, Harvard T.H. Chan School of Public Health</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8530-7228</contrib-id>
        <name>
          <surname>Zitnik</surname>
          <given-names>Marinka</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, Harvard Medical School</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
        <aff><institution>Broad Institute of MIT and Harvard</institution>, Cambridge, MA 02142, <country country="US">USA</country></aff>
        <aff><institution>Harvard Data Science Initiative</institution>, Cambridge, MA 02138, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5379-2502</contrib-id>
        <name>
          <surname>Cai</surname>
          <given-names>Tianxi</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, Harvard Medical School</institution>, Boston, MA 02115, <country country="US">USA</country></aff>
        <aff><institution>VA Boston Healthcare System</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
        <aff><institution>Mass General Brigham</institution>, Boston, MA 02130, <country country="US">USA</country></aff>
        <xref rid="btad085-cor1" ref-type="corresp"/>
        <!--tcai@hsph.harvard.edu-->
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Lu</surname>
          <given-names>Zhiyong</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btad085-cor1">To whom correspondence should be addressed. <email>tcai@hsph.harvard.edu</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>2</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-02-10">
      <day>10</day>
      <month>2</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>10</day>
      <month>2</month>
      <year>2023</year>
    </pub-date>
    <volume>39</volume>
    <issue>2</issue>
    <elocation-id>btad085</elocation-id>
    <history>
      <date date-type="received">
        <day>05</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>23</day>
        <month>12</month>
        <year>2022</year>
      </date>
      <date date-type="editorial-decision">
        <day>26</day>
        <month>1</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>08</day>
        <month>2</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>20</day>
        <month>2</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btad085.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Predicting molecule–disease indications and side effects is important for drug development and pharmacovigilance. Comprehensively mining molecule–molecule, molecule–disease and disease–disease semantic dependencies can potentially improve prediction performance.</p>
      </sec>
      <sec id="s2">
        <title>Methods</title>
        <p>We introduce a Multi-Modal REpresentation Mapping Approach to Predicting molecular-disease relations (M2REMAP) by incorporating clinical semantics learned from electronic health records (EHR) of 12.6 million patients. Specifically, M2REMAP first learns a multimodal molecule representation that synthesizes chemical property and clinical semantic information by mapping molecule chemicals via a deep neural network onto the clinical semantic embedding space shared by drugs, diseases and other common clinical concepts. To infer molecule–disease relations, M2REMAP combines multimodal molecule representation and disease semantic embedding to jointly infer indications and side effects.</p>
      </sec>
      <sec id="s3">
        <title>Results</title>
        <p>We extensively evaluate M2REMAP on molecule indications, side effects and interactions. Results show that incorporating EHR embeddings improves performance significantly, for example, attaining an improvement over the baseline models by 23.6% in PRC-AUC on indications and 23.9% on side effects. Further, M2REMAP overcomes the limitation of existing methods and effectively predicts drugs for novel diseases and emerging pathogens.</p>
      </sec>
      <sec id="s4">
        <title>Availability and implementation</title>
        <p>The code is available at <ext-link xlink:href="https://github.com/celehs/M2REMAP" ext-link-type="uri">https://github.com/celehs/M2REMAP</ext-link>, and prediction results are provided at <ext-link xlink:href="https://shiny.parse-health.org/drugs-diseases-dev/" ext-link-type="uri">https://shiny.parse-health.org/drugs-diseases-dev/</ext-link>.</p>
      </sec>
      <sec id="s6">
        <title>Supplementary information</title>
        <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>United States Government</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="9"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Traditional approaches to drug discovery mainly rely on bench experiments, which can be costly and time-consuming. Bringing a new drug to the market, on average, costs about 2.6 billion dollars (<xref rid="btad085-B8" ref-type="bibr">DiMasi <italic toggle="yes">et al.</italic>, 2016</xref>) and takes over 12 years (<xref rid="btad085-B26" ref-type="bibr">Mohs and Greig, 2017</xref>). With the increasing availability of large-scale biomedical data and biological knowledge sources, including molecule, chemical and biological properties, computational approaches to predicting molecule indications or side effects hold great promise in improving the efficiency of the drug discovery process. Even for drugs approved for specific indications, computational methods can identify new indications or side effects of a single drug or from drug–drug interactions. Such information can assist in drug re-purposing and reducing the risk of adverse drug events. Since we focus on small-molecule drugs, we use ‘drugs’ and ‘molecules’ interchangeably throughout this paper.</p>
    <p>Existing machine learning approaches to predicting drug–disease relations either rely on molecule chemical structure only (<xref rid="btad085-B49" ref-type="bibr">Zhou <italic toggle="yes">et al.</italic>, 2020</xref>) or further combine it with molecule biological properties (<xref rid="btad085-B19" ref-type="bibr">Jamal <italic toggle="yes">et al.</italic>, 2017</xref>; <xref rid="btad085-B22" ref-type="bibr">Lee and Chen, 2021</xref>; <xref rid="btad085-B24" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2012</xref>; <xref rid="btad085-B27" ref-type="bibr">Muñoz <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="btad085-B44" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2015</xref>) via multimodal methods. Chemical-only approach can effectively serve as a tool to virtually screen large chemical libraries and identify molecules to maximize the yield of downstream biological experiments. Multimodal approaches improve performance by further leveraging curated molecule properties, including target proteins, enzymes, pathways and phenotypic indications (<xref rid="btad085-B24" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2012</xref>; <xref rid="btad085-B27" ref-type="bibr">Muñoz <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="btad085-B44" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2015</xref>; <xref rid="btad085-B51" ref-type="bibr">Zitnik <italic toggle="yes">et al.</italic>, 2018</xref>). However, because chemical and biological properties do not contain clinical semantic information, existing methods do not comprehensively exploit drug–drug, disease–disease and drug–disease semantic dependencies. Drug–drug semantic dependency can be helpful for prediction since close molecules tend to treat or cause similar diseases (<xref rid="btad085-B27" ref-type="bibr">Muñoz <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="btad085-B45" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2016</xref>). For example, ‘statin’ drugs such as ‘atorvastatin’ and ‘fluvastatin’ are therapeutic in lowering cholesterol and the risk of cardiovascular diseases. Disease–disease dependency promotes semantically close diseases to be correlated as side effects or indications. For example, a drug that causes the side effect of ‘depression’ may also cause ‘anxiety’. Drug–disease dependency can serve as prior knowledge on a class of drugs and diseases, such as the high correlation between chemotherapeutic molecules and the side effect of ‘alopecia’. In this study, we hypothesize that effectively integrating such semantic dependency information with the chemical or biological properties can further improve the prediction.</p>
    <p>We aim to improve the prediction of molecule–disease relations by exploiting clinical semantic information learned from electronic health records (EHR). Previous studies have suggested that semantic relationships between clinical concepts, including drugs and diseases, can be captured in an embedding vector space derived from concept co-occurrence patterns extracted from large-scale EHR data (<xref rid="btad085-B3" ref-type="bibr">Beam <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="btad085-B16" ref-type="bibr">Hong <italic toggle="yes">et al.</italic>, 2021a</xref>). Clinical knowledge drawn from EHR data can augment existing knowledge on drug–disease relationships and drug chemical or biological properties. To synthesize information from molecule chemicals and EHR clinical semantics, we propose a Multi-Modal REpresentation Mapping Approach to Predicting molecular-disease relation (M2REMAP).</p>
    <p>Specifically, M2REMAP first learns from large-scale EHR data the clinical semantic embedding vectors of five broad categories of codified and narrative medical concepts, i.e. drug prescription codes, diagnostic billing codes, laboratory codes, procedure codes, as well as large scale clinical concept unique identifiers (CUIs) of the Unified Medical Language System (UMLS) extracted from free-text narrative notes via natural language processing (NLP). The NLP concepts cover a broad range of semantic types, including diseases, symptoms, clinical attributes and findings, and are particularly helpful in capturing drug side effects which are often symptoms and not well coded. For example, nausea is a side effect of many cancer treatments, but it is unlikely for cancer patients to receive a diagnostic code of nausea due to treatment side effects. In the second step, M2REMAP uses a deep neural network to train a multimodal molecule representation that fuses molecule chemicals and clinical semantics. Finally, M2REMAP infers molecule–disease relations by training a relation predictor that combines the molecule representation and disease semantic embedding to jointly learn indications and side effects.</p>
    <p>M2REMAP extends its generalization to novel diseases and novel molecules. This is achieved by performing a distribution matching of embedding vectors between large-scale molecules and EHR concepts. By representing molecules, indications, side effects, and varied clinical concepts in the same semantic embedding space, M2REMAP achieves improved generalization and high label efficiency across molecules and diseases, outperforming state-of-the-art approaches by 30.2% in PRC-AUC for side effect prediction. In addition, M2REMAP is a general molecule–disease relation predictor and addresses a critical unmet need, i.e. to effectively predict potential therapeutic molecules for novel diseases such as COVID-19, which do not have any annotated data for training.</p>
  </sec>
  <sec>
    <title>2 Materials and methods</title>
    <sec>
      <title>2.1 Overview</title>
      <p>M2REMAP infers molecule-disease relations based on molecule chemical structures and disease clinical embeddings. As outlined in <xref rid="btad085-F1" ref-type="fig">Figure 1</xref>, it consists of two steps: (i) <italic toggle="yes">Clinical embedding learning</italic> in which we learn semantic embeddings of clinical concepts from EHR data and transform large-scale molecule chemicals to the embedding space using a deep neural network; and (ii) <italic toggle="yes">Molecule–disease relation prediction</italic> in which we train a predictor network to infer molecule–disease relations by combining molecule chemicals and disease EHR embeddings. The key steps of M2REMAP are summarized in <xref rid="sup1" ref-type="supplementary-material">Supplementary Algorithm S1</xref>.</p>
      <fig position="float" id="btad085-F1">
        <label>Fig. 1.</label>
        <caption>
          <p>Overview of M2REMAP. By learning clinical semantic embeddings from EHR data, M2REMAP synthesized molecule chemicals and EHR semantics to attain multimodal molecule representation combined with disease EHR semantics to jointly infer indications and side effects</p>
        </caption>
        <graphic xlink:href="btad085f1" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>2.2 Clinical semantic learning</title>
      <sec>
        <title>2.2.1 EHR data</title>
        <p>We learn semantic embedding of clinical concepts using EHR data between 1999 and 2019 from the Department of Veterans Affairs (VA) Corporate Data Warehouse (CDW), containing data from over 150 VA facilities. We include all inpatient and outpatient data from 12.6 million patients who had at least one visit. Codes occurring multiple times for the same patient within the same day are counted once per day. We include five types of clinical concepts, (i) four broad classes of codified elements, namely drugs, diagnosis, procedures and lab measurements; as well as (ii) CUIs extracted from unstructured clinical notes via the NILE software (<xref rid="btad085-B41" ref-type="bibr">Yu <italic toggle="yes">et al.</italic>, 2013</xref>), restricting to a subset of clinically relevant semantic types. As in <xref rid="btad085-B16" ref-type="bibr">Hong <italic toggle="yes">et al.</italic> (2021a)</xref>, all drugs are aggregated at the ingredient level and mapped to RxNorm codes; diagnostic codes are mapped to PheCode; and procedure codes are mapped to the clinical classification software (CCS) categories (<ext-link xlink:href="https://www.hcup-us.ahrq.gov/toolssoftware/ccs_svcsproc/ccssvcproc.jsp" ext-link-type="uri">https://www.hcup-us.ahrq.gov/toolssoftware/ccs_svcsproc/ccssvcproc.jsp</ext-link>).</p>
      </sec>
      <sec>
        <title>2.2.2 Semantic embedding learning from EHR</title>
        <p>We obtain clinical semantic embeddings for EHR concepts based on the matrix factorization variant of the skip-gram algorithm, which only requires a pairwise co-occurrence matrix of the concepts as the input (<xref rid="btad085-B23" ref-type="bibr">Levy and Goldberg, 2014</xref>). Specifically, we count co-occurrences between any pair of clinical concepts within a 30-day window of each patient and aggregate across all patients. To ensure embedding quality, we remove co-occurrence pairs with a frequency below 5000. This results in 138 193 entities, with 9211 codified concepts and 128 982 CUIs. From the co-occurrence matrix, we compute the shifted positive pointwise mutual information (SPPMI) matrix and then obtain 500-dimensional semantic embedding vectors by performing a singular value decomposition (SVD) on the SPPMI matrix. The semantic relationship of EHR concepts is well encoded in the learned embedding space, as shown previously (<xref rid="btad085-B3" ref-type="bibr">Beam <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="btad085-B16" ref-type="bibr">Hong <italic toggle="yes">et al.</italic>, 2021a</xref>).</p>
      </sec>
      <sec>
        <title>2.2.3 Molecule embedding learning</title>
        <p>We next map molecule chemical structures onto the EHR semantic embedding space via a supervised deep neural network. The molecules with the corresponding EHR semantic embedding are denoted as ‘mapped’ and the rest as ‘unmapped’. Based on those ‘mapped’ molecules, we train a supervised deep neural network that maps their chemical structures onto semantic embeddings, minimizing the <italic toggle="yes">L</italic><sub>2</sub> distance between the EHR embedding of the molecule and the mapped embedding.</p>
        <p>To map the molecule structure to the space of EHR embeddings, the molecule-embedding mapping module consists of a Feature Extractor network (<bold>E</bold>) that transforms molecule chemical structures into multimodal representation and a Linear Mapper (<bold>M</bold>) that distills semantic embeddings from molecule representation. The feature extractor receives molecular SMILES as inputs and mainly consists of an embedding layer, 1D convolutional operations to capture the local interactions between tokens, and a bi-directional GRUs layer to capture the long-range sequential dependency. The CNN+bi-GRU architecture has performed well in other molecular computational tasks (<xref rid="btad085-B14" ref-type="bibr">Gómez-Bombarelli <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="btad085-B43" ref-type="bibr">Zagidullin <italic toggle="yes">et al.</italic>, 2021</xref>). We discuss alternative architectures for this step in the discussion section. We minimize the mean squared prediction error
<disp-formula id="E1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">mapped</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">E</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>to train <bold>E</bold> and <bold>M</bold> simultaneously, where <italic toggle="yes">x<sub>i</sub></italic> is from <inline-formula id="IE1"><mml:math id="IM1" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">mapped</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> which consists of ‘mapped’ molecules and <inline-formula id="IE2"><mml:math id="IM2" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> denotes its semantic embedding vector.</p>
        <p>We then employ transfer learning to generalize the embedding learning to “unmapped” or novel molecules not included in EHR. Specifically, we additionally encourage the embeddings of large-scale molecule chemicals from the Drugbank (<xref rid="btad085-B39" ref-type="bibr">Wishart <italic toggle="yes">et al.</italic>, 2018</xref>) to be encoded by <bold>E</bold> onto the same semantic embedding space. This is achieved by requiring “unmapped” molecules to follow the same embedding distribution as those EHR medical concepts. To this end, the feature extractor <bold>E</bold> is optimized with an additional objective <inline-formula id="IE3"><mml:math id="IM3" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi>u</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> to measure the embedding distribution discrepancy between Drugbank molecules and EHR clinical concepts. Motivated by adversarial transfer learning, we train an additional discriminator network <inline-formula id="IE4"><mml:math id="IM4" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> to distinguish the EHR embeddings from the molecule embeddings and quantify their distribution discrepancy. The <bold>E</bold>, together with <bold>M</bold>, is then trained to transform novel molecules into semantic embeddings with distributions similar to the EHR concepts. Such a <italic toggle="yes">minmax</italic> learning procedure is formulated as:
<disp-formula id="E2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:mtable><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:munder><mml:mrow><mml:mi>min</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold">E</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">M</mml:mi></mml:mrow></mml:munder><mml:munder><mml:mrow><mml:mi>max</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">novel</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold">E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo> </mml:mo><mml:mtext>log</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">E</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold">E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">ehr</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo> </mml:mo><mml:mtext>log</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>where <italic toggle="yes">x<sub>i</sub></italic> denotes a molecule chemical structure from Drugbank <italic toggle="yes">D<sub>db</sub></italic> and <italic toggle="yes">e<sub>j</sub></italic> is a semantic embedding from <inline-formula id="IE5"><mml:math id="IM5" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">ehr</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> which consists of all clinical concepts. We use a multi-layer perception network as the discriminator <inline-formula id="IE6"><mml:math id="IM6" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> parameterized by <inline-formula id="IE7"><mml:math id="IM7" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mo>θ</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>.</p>
      </sec>
    </sec>
    <sec>
      <title>2.3 Molecule–disease relation prediction</title>
      <sec>
        <title>2.3.1 Multimodal molecule representation</title>
        <p>To optimize the prediction of molecule–disease relations, M2REMAP further fine-tunes the representation of molecules based on observed labels on the known relationships. To this end, the feature extractor <bold>E</bold> is further refined in a multi-task manner to minimize the two aforementioned embedding learning losses <inline-formula id="IE8"><mml:math id="IM8" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> in (1) and <inline-formula id="IE9"><mml:math id="IM9" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">novel</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> in (2) and also the binary cross-entropy prediction loss:
<disp-formula id="E3"><label>(3)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:mtable><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">pred</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>∼</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">label</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mo> </mml:mo><mml:mtext>log</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">E</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mo>−</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>*</mml:mo><mml:mo> </mml:mo><mml:mtext>log</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="bold">P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">E</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>where <italic toggle="yes">i</italic> indexes the relationship pair with label <italic toggle="yes">y<sub>i</sub></italic> sampled from annotated molecule–disease dataset <inline-formula id="IE10"><mml:math id="IM10" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">label</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, and <inline-formula id="IE11"><mml:math id="IM11" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> denotes the embedding of disease <italic toggle="yes">d<sub>i</sub></italic> from <inline-formula id="IE12"><mml:math id="IM12" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">ehr</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>. We next detail the construction of the relation predictor <bold>P</bold>, which takes separate forms for indications versus side effects.</p>
      </sec>
      <sec>
        <title>2.3.2 Relation learning</title>
        <p>To comprehensively capture drug–drug, disease–disease and drug–disease semantic dependencies, M2REMAP infers general molecule–disease relations by sharing the pairwise relation predictor <bold>P</bold> across multiple diseases and drugs. To achieve this, <bold>P</bold> combines multimodal molecule representation and disease semantics and is trained to learn invariant relation representations across novel molecule–disease combinations of novel molecules or diseases, as shown in <xref rid="btad085-F1" ref-type="fig">Figure 1</xref>. Therefore, <bold>P</bold> is additionally optimized by <inline-formula id="IE13"><mml:math id="IM13" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">novel</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">rela</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>:
<disp-formula id="E4"><label>(4)</label><mml:math id="M4" display="block" overflow="scroll"><mml:mrow><mml:mtable><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:munder><mml:mrow><mml:mi>min</mml:mi></mml:mrow><mml:mi mathvariant="bold">P</mml:mi></mml:munder><mml:munder><mml:mrow><mml:mi>max</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">rela</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">novel</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">rela</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold">E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">ehr</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo> </mml:mo><mml:mtext>log</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">rela</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">E</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold">E</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>∼</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">label</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo> </mml:mo><mml:mtext>log</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">rela</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">E</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>where <inline-formula id="IE14"><mml:math id="IM14" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">rela</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, with the same architecture as the <inline-formula id="IE15"><mml:math id="IM15" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, is a discriminator network trained to distinguish the relation representation of annotated molecule–disease combinations from those of novel combinations. Molecule <italic toggle="yes">x<sub>j</sub></italic> and <italic toggle="yes">d<sub>j</sub></italic>, with embedding <inline-formula id="IE16"><mml:math id="IM16" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, are from the annotated molecule–disease data <inline-formula id="IE17"><mml:math id="IM17" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">label</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>.</p>
        <p>Integrating all steps, the M2REMAP model is trained with a joint objective <inline-formula id="IE18"><mml:math id="IM18" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">joint</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, which is formulated as:
<disp-formula id="E5"><label>(5)</label><mml:math id="M5" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">joint</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">pred</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">indi</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">pred</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">side</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mo>β</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo>γ</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">novel</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mo>δ</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">novel</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">rela</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <inline-formula id="IE19"><mml:math id="IM19" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">pred</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">indi</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE20"><mml:math id="IM20" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">pred</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">side</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> denote the prediction loss, defined in <xref rid="E3" ref-type="disp-formula">Equation (3)</xref>, of indication and side effects, respectively. <italic toggle="yes">β</italic>, <italic toggle="yes">γ</italic> and <italic toggle="yes">δ</italic> are hyper-parameters that balance the multiple objectives. When minimizing <inline-formula id="IE21"><mml:math id="IM21" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">joint</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, some nuisance parameters should be optimized using specific components. For example, the embedding mapper <bold>M</bold> can be optimized only using <inline-formula id="IE22"><mml:math id="IM22" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>. The hyper-parameter selection is detailed in <xref rid="sup1" ref-type="supplementary-material">Supplementary Note S6</xref>.</p>
      </sec>
      <sec>
        <title>2.3.3 Semantic-guided sampling of negative drug–disease relations</title>
        <p>Each drug is typically reported to have some indications or side effects, often noted in the widely used SIDER (<xref rid="btad085-B24" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2012</xref>) and FDA reports (<xref rid="btad085-B46" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2021</xref>), which constitute the positive drug–disease pairs. However, validated annotations on negative drug–disease relationship pairs are scarce. Most existing methods treat the unreported drug–disease pairs as the negatives (<xref rid="btad085-B27" ref-type="bibr">Muñoz <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="btad085-B40" ref-type="bibr">Yamanishi <italic toggle="yes">et al.</italic>, 2012</xref>; <xref rid="btad085-B45" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2016</xref>). This could be problematic and result in false negatives due to incomplete annotations, causing bias in both training and evaluation. To alleviate this issue, M2REMAP guides the selection of negative molecule–disease relations by exploiting the semantic similarity as prior knowledge. Specifically, for each drug, we require the negative indications or side effects to be semantically dissimilar to all of the drug’s reported or annotated indications or side effects. In this case, for a drug with the partially annotated side effect of ‘C0011603 (dermatitides)’, the side effects of ‘C0037274 (dermatosis)’ and ‘C0023530 (itch)’, which co-occur with ‘C0011603 (dermatitides)’ frequently as side effects, would not be incorrectly treated as negatives. To achieve this, we measure the disease closeness using the semantic cosine similarity and remove the diseases from the negatives with high cosine similarity to the annotated diseases.</p>
        <p>In addition, we also study using validated negative drug side effects pairs for extra validations by creating a small dataset based on literature reviews of clinical-trials meta-analysis results (<xref rid="btad085-B9" ref-type="bibr">Edwards <italic toggle="yes">et al.</italic>, 1999</xref>; <xref rid="btad085-B11" ref-type="bibr">Fioravanti <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="btad085-B13" ref-type="bibr">Golder <italic toggle="yes">et al.</italic>, 2011</xref>), which is provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Note S7</xref>.</p>
      </sec>
    </sec>
  </sec>
  <sec>
    <title>3 Experiments</title>
    <p>We validate M2REMAP in three parts. (i) We visualize the learned EHR clinical semantic embedding vectors and show that it captures drug–disease semantic relationship; (ii) we numerically evaluate M2REMAP in learning molecule indications and side effects using annotated datasets; (iii) we investigate the novel prediction of molecule–disease relations.</p>
    <sec>
      <title>3.1 EHR embedding visualization</title>
      <sec>
        <title>3.1.1 Settings</title>
        <p>We first examine the relationships between drugs and diseases by visualizing the EHR embedding space. The embedding vectors are first reduced to two dimensions via PCA and then visualized using t-SNE (<xref rid="btad085-B35" ref-type="bibr">Van der Maaten and Hinton, 2008</xref>). We visualize 46 cancer drugs (<ext-link xlink:href="https://www.cancer.gov/about-cancer/treatment/drugs" ext-link-type="uri">https://www.cancer.gov/about-cancer/treatment/drugs</ext-link>) and 26 psychotropic drugs (<ext-link xlink:href="https://www.healthpartners.com/ucm/groups/public/@hp/@public/documents/documents/entry_194823.pdf" ext-link-type="uri">https://www.healthpartners.com/ucm/groups/public/@hp/@public/documents/documents/entry_194823.pdf</ext-link>), which are commonly used in clinical settings, and their related top-30 indications reported on PrimeKG dataset (<xref rid="btad085-B5" ref-type="bibr">Chandak <italic toggle="yes">et al.</italic>, 2022</xref>) in <xref rid="btad085-F2" ref-type="fig">Figure 2a</xref> and their top-30 reported side effects on the SIDER 4.1 dataset (<xref rid="btad085-B21" ref-type="bibr">Kuhn <italic toggle="yes">et al.</italic>, 2016</xref>) in <xref rid="btad085-F2" ref-type="fig">Figure 2b</xref>. Meanwhile, we also visualize all EHR concepts and Drugbank molecules in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S3a</xref>, showing that they are well-aligned in the embedding space.</p>
        <fig position="float" id="btad085-F2">
          <label>Fig. 2</label>
          <caption>
            <p>Drug–disease embedding visualization. We visualize the EHR semantic embedding of cancer and psychotropic drugs and their reported indications and side effects. (<bold>a</bold>) drugs and indications; (<bold>b</bold>) drugs and side effects</p>
          </caption>
          <graphic xlink:href="btad085f2" position="float"/>
        </fig>
      </sec>
      <sec>
        <title>3.1.2 Results</title>
        <p>As shown in <xref rid="btad085-F2" ref-type="fig">Figure 2a</xref>, cancer drugs generally cluster together in the semantic embedding space and are far away from the psychotropic drugs. Most of the indications are close to the corresponding drugs, and the indications of cancer drugs are distinct from those of psychotropic drugs in the embedding space. That is, indications are an important indicator of drug semantics, which explains why observing indications considerably improves the learning of drug side effects in (<xref rid="btad085-B24" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2012</xref>; <xref rid="btad085-B44" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2015</xref>). A few drugs indicated for cancers of specific organs are far from the majority in the embedding space. For example, ‘Sorafenib’ is used for ‘Renal cell carcinoma’, and ‘Temozolomide’ is used for brain cancer and is reasonably close to psychotropic drugs in the embedding space.</p>
        <p>The semantic dependencies between drugs and side effects are more complex than those between drugs and indications. Side effects generally do not cluster together with the corresponding medications in the embedding space, as shown in <xref rid="btad085-F2" ref-type="fig">Figure 2b</xref>. This is because, in contrast to the high co-occurrence between indications and the corresponding drugs in EHR data, side effects occur less frequently and hence have fewer co-occurrences with the corresponding drugs. In addition, many side effects, such as ‘nausea’ and ‘decreased appetite’, are often not specific and shared across drugs.</p>
      </sec>
    </sec>
    <sec>
      <title>3.2 Molecule indication prediction</title>
      <sec>
        <title>3.2.1 Settings</title>
        <p>Based on annotated drug–disease indications, we comprehensively evaluate M2REMAP under three different settings. (i) <italic toggle="yes">Cross-molecule validation</italic> where we randomly choose 70% molecules for training, 10% for validation and 20% for evaluation, which is the default setting unless noted; (ii) <italic toggle="yes">Cross-year validation</italic> where we use the drugs reported in SIDER 4.1 (<xref rid="btad085-B21" ref-type="bibr">Kuhn <italic toggle="yes">et al.</italic>, 2016</xref>), marketed before 2015, for training and the drugs marketed since 2015 for evaluation; and (iii) <italic toggle="yes">Cross-disease validation</italic> in which we randomly select 70%, 10% and 20% diseases for training, validation and evaluation, respectively. Cross-year validation aims to evaluate model generalization to predict newly marketed drugs with already on-market drugs as training. Cross-disease validation test model ability to generalize to novel diseases not encountered by the model during training.</p>
        <p>We experiment on PrimeKG (<xref rid="btad085-B5" ref-type="bibr">Chandak <italic toggle="yes">et al.</italic>, 2022</xref>), which includes annotated drug-indication relations and SIDER 4.1 (<xref rid="btad085-B21" ref-type="bibr">Kuhn <italic toggle="yes">et al.</italic>, 2016</xref>), which consists of reported side effects for joint training. There are 349 indications included that are observed by at least three drugs in PrimeKG. Both datasets are detailed in <xref rid="btad085-T1" ref-type="table">Table 1</xref>. Instead of using the raw 500-D VA embedding, we reduce its dimensionality to 100 by performing PCA among the drugs and diseases observed in PrimeKG and SIDER 4.1. Sensitivity analysis on the embedding dimensionality is provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Note S9</xref>. In addition to the proposed M2REMAP, we report five variants of M2REMAP to show how different components affect the performance: (i) <italic toggle="yes">M2REMAP(w/o multimodal)</italic> in which the molecule representation is not trained to incorporate EHR semantic information, i.e. removing <inline-formula id="IE23"><mml:math id="IM23" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE24"><mml:math id="IM24" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">novel</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> from the objective function; (ii) <italic toggle="yes">M2REMAP(w/o semantic)</italic> in which no EHR semantic information is used and diseases are represented by one-hot encoding; (iii) <italic toggle="yes">M2REMAP(w/o joint)</italic> in which indications and side effects are trained separately; (iv) <italic toggle="yes">M2REMAP</italic>(<italic toggle="yes">w/o</italic> <inline-formula id="IE25"><mml:math id="IM25" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">novel</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>) in which components for generalizing to novel molecules and diseases, <inline-formula id="IE26"><mml:math id="IM26" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">novel</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">emb</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE27"><mml:math id="IM27" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">novel</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">rela</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, are removed; and (v) <italic toggle="yes">M2REMAP(base)</italic> denotes the baseline deep neural network without incorporating semantics and joint training. In the base model, the diseases are one-hot encoded. Still, the predictor is shared across all diseases, a practice found to achieve better performance than training each disease independently (<xref rid="btad085-B24" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2012</xref>; <xref rid="btad085-B27" ref-type="bibr">Muñoz <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="btad085-B45" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2016</xref>). Since the drug indication and drug side effects are jointly trained, diseases that are reported as indications and side effects simultaneously would be treated as indications only. To measure the performance, we report the area under the receiver operating characteristics curve (ROC-AUC), the area under the precision-recall curve (PRC-AUC), and the average precision at k (AP@k). The results are averaged over five random partitions of the training versus test data.</p>
        <table-wrap position="float" id="btad085-T1">
          <label>Table 1.</label>
          <caption>
            <p>Datasets details of the annotated drug–disease relations</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="center" span="1"/>
              <col valign="top" align="char" char="." span="1"/>
              <col valign="top" align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1">Setting</th>
                <th rowspan="1" colspan="1">Dataset</th>
                <th rowspan="1" colspan="1">Drug</th>
                <th rowspan="1" colspan="1">Disease</th>
                <th rowspan="1" colspan="1">Sample</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Drug indications</td>
                <td rowspan="1" colspan="1">PrimeKG (<xref rid="btad085-B5" ref-type="bibr">Chandak <italic toggle="yes">et al.</italic>, 2022</xref>)</td>
                <td rowspan="1" colspan="1">1281</td>
                <td rowspan="1" colspan="1">349</td>
                <td rowspan="1" colspan="1">3718</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">SIDER-PrimeKG</td>
                <td rowspan="1" colspan="1">1242:39</td>
                <td rowspan="1" colspan="1">349</td>
                <td rowspan="1" colspan="1">3718</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Side effects(mono)</td>
                <td rowspan="1" colspan="1">SIDER(Liu) (<xref rid="btad085-B24" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2012</xref>)</td>
                <td rowspan="1" colspan="1">769</td>
                <td rowspan="1" colspan="1">1228</td>
                <td rowspan="1" colspan="1">43719</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">SIDER(Zhang) (<xref rid="btad085-B44" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2015</xref>)</td>
                <td rowspan="1" colspan="1">747:263</td>
                <td rowspan="1" colspan="1">2853</td>
                <td rowspan="1" colspan="1">80177</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">SIDER 4.1 (<xref rid="btad085-B21" ref-type="bibr">Kuhn <italic toggle="yes">et al.</italic>, 2016</xref>)</td>
                <td rowspan="1" colspan="1">1355</td>
                <td rowspan="1" colspan="1">2923</td>
                <td rowspan="1" colspan="1">99159</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">SIDER-FAERS(mono)</td>
                <td rowspan="1" colspan="1">1355:159</td>
                <td rowspan="1" colspan="1">3355</td>
                <td rowspan="1" colspan="1">104223</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Side effects(DDI)</td>
                <td rowspan="1" colspan="1">TWOSIDES (<xref rid="btad085-B42" ref-type="bibr">Yu <italic toggle="yes">et al.</italic>, 2021</xref>)</td>
                <td rowspan="1" colspan="1">645</td>
                <td rowspan="1" colspan="1">200</td>
                <td rowspan="1" colspan="1">54261</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">FAERS2021 (<xref rid="btad085-B46" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2021</xref>)</td>
                <td rowspan="1" colspan="1">925</td>
                <td rowspan="1" colspan="1">2453</td>
                <td rowspan="1" colspan="1">70385</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">SIDER-FAERS(DDI)</td>
                <td rowspan="1" colspan="1">846:79</td>
                <td rowspan="1" colspan="1">2453</td>
                <td rowspan="1" colspan="1">70385</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="tblfn1">
              <p><italic toggle="yes">Note</italic>: The PrimeKG consists of drug-indication pairs. Both mono-drug and drug–drug interaction (DDI) are included for side effects.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec>
        <title>3.2.2 Results</title>
        <p>As shown in <xref rid="btad085-T2" ref-type="table">Table 2</xref>, M2REMAP achieves a PRC-AUC of 0.649, which improves from the 0.525 of the baseline model by 23.6%. The AP@3 is 0.295, which is reasonably high considering that there are only 2.9 reported indications on average for each molecule. Compared to the LSP-ADR (<xref rid="btad085-B24" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2012</xref>) and MEDICASCY (<xref rid="btad085-B49" ref-type="bibr">Zhou <italic toggle="yes">et al.</italic>, 2020</xref>), performance gains of M2REMAP are considerable, outperforming state-of-the-art chemical-only model, MEDICASCY, by 5.9% in ROC-AUC and 37.5% in PRC-AUC. Without incorporating EHR embeddings, M2REMAP(w/o semantic) performs only comparably to the baseline model. Reduced version M2REMAP(w/o multimodal) performs worse than the baseline model in PRC-AUC and AP@3, which verifies the importance of multimodal molecule representation. In addition, we find that jointly learning indications and side effects helps boost performance. This is consistent with the results reported in <xref rid="btad085-B49" ref-type="bibr">Zhou <italic toggle="yes">et al.</italic> (2020)</xref>, <xref rid="btad085-B45" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic> (2016)</xref> and <xref rid="btad085-B24" ref-type="bibr">Liu <italic toggle="yes">et al.</italic> (2012)</xref>. The training objective <inline-formula id="IE28"><mml:math id="IM28" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">novel</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> improves model generalization cross molecules and brings improvements of 5.5% in PRC-AUC, 2.0% in ROC-AUC and 6.1% in AP@3.</p>
        <table-wrap position="float" id="btad085-T2">
          <label>Table 2.</label>
          <caption>
            <p>Results of molecule indication learning on the PrimeKG dataset (<xref rid="btad085-B5" ref-type="bibr">Chandak <italic toggle="yes">et al.</italic>, 2022</xref>)</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="char" char="." span="1"/>
              <col valign="top" align="char" char="." span="1"/>
              <col valign="top" align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1">Methods</th>
                <th rowspan="1" colspan="1">ROC-AUC</th>
                <th rowspan="1" colspan="1">PRC-AUC</th>
                <th rowspan="1" colspan="1">AP@3</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">LSP-ADR (<xref rid="btad085-B24" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2012</xref>)</td>
                <td rowspan="1" colspan="1">0.821</td>
                <td rowspan="1" colspan="1">0.439</td>
                <td rowspan="1" colspan="1">0.123</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">MEDICASCY (<xref rid="btad085-B49" ref-type="bibr">Zhou <italic toggle="yes">et al.</italic>, 2020</xref>)</td>
                <td rowspan="1" colspan="1">0.833</td>
                <td rowspan="1" colspan="1">0.472</td>
                <td rowspan="1" colspan="1">0.173</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">M2REMAP(base)</td>
                <td rowspan="1" colspan="1">0.826</td>
                <td rowspan="1" colspan="1">0.525</td>
                <td rowspan="1" colspan="1">0.262</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">M2REMAP(w/o multimodal)</td>
                <td rowspan="1" colspan="1">0.846</td>
                <td rowspan="1" colspan="1">0.458</td>
                <td rowspan="1" colspan="1">0.225</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">M2REMAP(w/o semantic)</td>
                <td rowspan="1" colspan="1">0.849</td>
                <td rowspan="1" colspan="1">0.517</td>
                <td rowspan="1" colspan="1">0.268</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">M2REMAP(w/o joint)</td>
                <td rowspan="1" colspan="1">0.853</td>
                <td rowspan="1" colspan="1">0.577</td>
                <td rowspan="1" colspan="1">0.257</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">M2REMAP(w/o <inline-formula id="IE29"><mml:math id="IM29" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="script" class="calligraphy">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">novel</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>)</td>
                <td rowspan="1" colspan="1">0.865</td>
                <td rowspan="1" colspan="1">0.615</td>
                <td rowspan="1" colspan="1">0.278</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">M2REMAP</td>
                <td rowspan="1" colspan="1">
                  <bold>0.882</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.649</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.295</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">M2REMAP(cross-year)</td>
                <td rowspan="1" colspan="1">0.853</td>
                <td rowspan="1" colspan="1">0.573</td>
                <td rowspan="1" colspan="1">0.256</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">M2REMAP(cross-disease)</td>
                <td rowspan="1" colspan="1">0.758</td>
                <td rowspan="1" colspan="1">0.414</td>
                <td rowspan="1" colspan="1">0.175</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Random guess(cross-disease)</td>
                <td rowspan="1" colspan="1">0.509</td>
                <td rowspan="1" colspan="1">0.058</td>
                <td rowspan="1" colspan="1">0.022</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>For the cross-disease prediction, namely, to predict the relations involving novel diseases, M2REMAP drops by 36.2% in PRC-AUC and by 14.1% in ROC-AUC over cross-molecule, which is substantially worse than the cross-year setting. One of the reasons is that M2REMAP is trained from &lt;350 diseases, thus with weaker cross-disease generalization than over cross-molecule. Since existing methods require annotated data for predicted diseases and cannot always successfully generalize to novel diseases, M2REMAP encouragingly outperforms the random guess by 613.8% in PRC-AUC and 48.9% in ROC-AUC. In <xref rid="sup1" ref-type="supplementary-material">Supplementary Note S8</xref>, we provide a detailed analysis of performance gains across different drug/indication groups brought by the EHR embedding vectors. We observe that drugs from ‘musculo-skeletal system’ and ‘respiratory system’ benefit the most from the semantic embedding, while for diseases, the improvement from ‘nervous system diseases’ is the most significant, followed by ‘metabolic diseases’.</p>
      </sec>
    </sec>
    <sec>
      <title>3.3 Side effects prediction</title>
      <sec>
        <title>3.3.1 Settings</title>
        <p>For side effect prediction, we evaluate drug side effects caused by a single drug or drug interactions. The same three settings as in the molecule indication prediction are used. For mono-drug side effects, we experiment on SIDER(Liu) (<xref rid="btad085-B24" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2012</xref>), SIDER(Zhang) (<xref rid="btad085-B44" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2015</xref>), nd SIDER-FAERS(mono) which aims for cross-year validation by learning on SIDER 4.1 (<xref rid="btad085-B21" ref-type="bibr">Kuhn <italic toggle="yes">et al.</italic>, 2016</xref>) with annotated drugs marketed before 2015 and evaluating on FAERS2021 (<xref rid="btad085-B46" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2021</xref>) with newly marketed drugs since 2015. For side effects by drug–drug interactions, we evaluate on TWOSIDES (<xref rid="btad085-B51" ref-type="bibr">Zitnik <italic toggle="yes">et al.</italic>, 2018</xref>), following the protocols of <xref rid="btad085-B42" ref-type="bibr">Yu <italic toggle="yes">et al.</italic> (2021)</xref> and FAERS2021 (<xref rid="btad085-B46" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2021</xref>). Of note, for DDIs, most existing methods (<xref rid="btad085-B15" ref-type="bibr">Grover and Leskovec, 2016</xref>; <xref rid="btad085-B42" ref-type="bibr">Yu <italic toggle="yes">et al.</italic>, 2021</xref>; <xref rid="btad085-B51" ref-type="bibr">Zitnik <italic toggle="yes">et al.</italic>, 2018</xref>) assume all drugs available for training and aim to learn models that predict the interaction by their new combinations. To study the generalization to novel diseases, we construct SIDER-FAERS(DDIs) based on FAERS2021 annotations, namely using drugs in SIDER 4.1 (<xref rid="btad085-B21" ref-type="bibr">Kuhn <italic toggle="yes">et al.</italic>, 2016</xref>) for training and the rest of the drugs in FAERS2021 for evaluation. The datasets are detailed in <xref rid="btad085-T1" ref-type="table">Table 1</xref>.</p>
      </sec>
      <sec>
        <title>3.3.2 Results</title>
        <p>As shown in <xref rid="btad085-T3" ref-type="table">Table 3</xref> for mono-drug side effects, M2REMAP attains substantially higher PRC-AUC compared to ISRNS (<xref rid="btad085-B48" ref-type="bibr">Zheng <italic toggle="yes">et al.</italic>, 2019</xref>), the best performing existing method evaluated on SIDER(Liu), and MEDICASCY (<xref rid="btad085-B49" ref-type="bibr">Zhou <italic toggle="yes">et al.</italic>, 2020</xref>), the SOTA model on SIDER(Zhang). M2REMAP improves the PRC-AUC from 0.542 of ISRNS to 0.626 on the SIDER(Liu), and from 0.394 of MEDICASCY to 0.513 on SIDER(Zhang). <xref rid="sup1" ref-type="supplementary-material">Supplementary Note S8</xref> provides a detailed analysis of performance gains across different drug/side effect groups brought by the EHR embedding vectors. We observe that drugs from different groups consistently benefit from the semantic embedding, and the improvements from ‘respiratory system’ and ‘dermatologicals’ are the most substantial. When grouping side effects into different categories, most categories attain higher accuracy, with the ‘eye/ear diseases’ benefiting the most, followed by ‘mental disorders’.</p>
        <table-wrap position="float" id="btad085-T3">
          <label>Table 3.</label>
          <caption>
            <p>Results of predicting mono-molecule side effects</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="char" char="." span="1"/>
              <col valign="top" align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1">Dataset</th>
                <th rowspan="1" colspan="1">Method</th>
                <th rowspan="1" colspan="1">Feature</th>
                <th rowspan="1" colspan="1">ROC-AUC</th>
                <th rowspan="1" colspan="1">PRC-AUC</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">SIDER(Liu)</td>
                <td rowspan="1" colspan="1">LSP-ADR (<xref rid="btad085-B24" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2012</xref>)</td>
                <td rowspan="1" colspan="1">Multimodal</td>
                <td rowspan="1" colspan="1">0.885</td>
                <td rowspan="1" colspan="1">0.251</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">FS-MLKNN (<xref rid="btad085-B44" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2015</xref>)</td>
                <td rowspan="1" colspan="1">Multimodal</td>
                <td rowspan="1" colspan="1">0.903</td>
                <td rowspan="1" colspan="1">0.480</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">LNSM-CMI (<xref rid="btad085-B45" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2016</xref>)</td>
                <td rowspan="1" colspan="1">Multimodal</td>
                <td rowspan="1" colspan="1">0.909</td>
                <td rowspan="1" colspan="1">0.491</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">ISRNS (<xref rid="btad085-B48" ref-type="bibr">Zheng <italic toggle="yes">et al.</italic>, 2019</xref>)</td>
                <td rowspan="1" colspan="1">Multimodal</td>
                <td rowspan="1" colspan="1">0.909</td>
                <td rowspan="1" colspan="1">0.542</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">M2REMAP(base)</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.905</td>
                <td rowspan="1" colspan="1">0.517</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">M2REMAP</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">
                  <bold>0.915</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.626</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">SIDER(Zhang)</td>
                <td rowspan="1" colspan="1">MLP (<xref rid="btad085-B27" ref-type="bibr">Muñoz <italic toggle="yes">et al.</italic>, 2019</xref>)</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.894</td>
                <td rowspan="1" colspan="1">0.355</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">FS-MLKNN (<xref rid="btad085-B44" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2015</xref>)</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.872</td>
                <td rowspan="1" colspan="1">0.365</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">LNSM-CMI (<xref rid="btad085-B45" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2016</xref>)</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.885</td>
                <td rowspan="1" colspan="1">0.380</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">MEDICASCY (<xref rid="btad085-B49" ref-type="bibr">Zhou <italic toggle="yes">et al.</italic>, 2020</xref>)</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">
                  <bold>0.902</bold>
                </td>
                <td rowspan="1" colspan="1">0.394</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">M2REMAP(base)</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.889</td>
                <td rowspan="1" colspan="1">0.405</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">M2REMAP</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.901</td>
                <td rowspan="1" colspan="1">
                  <bold>0.513</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">SIDER-FAERS(cross-year)</td>
                <td rowspan="1" colspan="1">M2REMAP</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.873</td>
                <td rowspan="1" colspan="1">0.507</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">SIDER 4.1(cross-disease)</td>
                <td rowspan="1" colspan="1">M2REMAP</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.788</td>
                <td rowspan="1" colspan="1">0.288</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Random guess</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.513</td>
                <td rowspan="1" colspan="1">0.065</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The results of side effects caused by drug–drug interactions are reported in <xref rid="btad085-T4" ref-type="table">Table 4</xref>. For TWOSIDES, which reports each side effect with at least 900 drug–drug combinations, we report AP<inline-formula id="IE30"><mml:math id="IM30" display="inline" overflow="scroll"><mml:mo>@</mml:mo></mml:math></inline-formula>50, while for FAERS2021, which reports each side effect only with 25.9 drug pairs on average, we report AP<inline-formula id="IE31"><mml:math id="IM31" display="inline" overflow="scroll"><mml:mo>@</mml:mo></mml:math></inline-formula>3. On the TWOSIDES, M2REMAP attains PRC-AUC and AP<inline-formula id="IE32"><mml:math id="IM32" display="inline" overflow="scroll"><mml:mo>@</mml:mo></mml:math></inline-formula>50 of 0.978 and 0.993, respectively, which are substantially higher than the 0.934 and 0.888 of the SOTA method SumGNN (<xref rid="btad085-B42" ref-type="bibr">Yu <italic toggle="yes">et al.</italic>, 2021</xref>). For drug–drug interaction with novel drugs, M2REMAP is observed with significant performance drops on the SIDER-FAERS, with PRC-AUC falling by 7.9% and AP@3 by 11.9%, compared to the cross-molecule validation on FAERS2021. The results indicate that its challenging for drug–drug interaction learning to generalize to novel drugs.</p>
        <table-wrap position="float" id="btad085-T4">
          <label>Table 4.</label>
          <caption>
            <p>Results of molecule side effects caused by drug–drug interactions</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="char" char="." span="1"/>
              <col valign="top" align="char" char="." span="1"/>
              <col valign="top" align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1">Dataset</th>
                <th rowspan="1" colspan="1">Method</th>
                <th rowspan="1" colspan="1">Feature</th>
                <th rowspan="1" colspan="1">ROC-AUC</th>
                <th rowspan="1" colspan="1">PRC-AUC</th>
                <th rowspan="1" colspan="1">AP@k</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">TWOSIDES</td>
                <td rowspan="1" colspan="1">MLP (<xref rid="btad085-B31" ref-type="bibr">Rogers and Hahn, 2010</xref>)</td>
                <td rowspan="1" colspan="1">Multimodal</td>
                <td rowspan="1" colspan="1">0.826</td>
                <td rowspan="1" colspan="1">0.812</td>
                <td rowspan="1" colspan="1">0.735 (@50)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Node2Vec (<xref rid="btad085-B15" ref-type="bibr">Grover and Leskovec, 2016</xref>)</td>
                <td rowspan="1" colspan="1">Multimodal</td>
                <td rowspan="1" colspan="1">0.907</td>
                <td rowspan="1" colspan="1">0.889</td>
                <td rowspan="1" colspan="1">0.830 (@50)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">SumGNN (<xref rid="btad085-B42" ref-type="bibr">Yu <italic toggle="yes">et al.</italic>, 2021</xref>)</td>
                <td rowspan="1" colspan="1">Multimodal</td>
                <td rowspan="1" colspan="1">0.949</td>
                <td rowspan="1" colspan="1">0.934</td>
                <td rowspan="1" colspan="1">0.888 (@50)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">M2REMAP(base)</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.901</td>
                <td rowspan="1" colspan="1">0.912</td>
                <td rowspan="1" colspan="1">0.897 (@50)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">M2REMAP</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">
                  <bold>0.986</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.978</bold>
                </td>
                <td rowspan="1" colspan="1"><bold>0.993</bold> (@50)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">FAERS2021</td>
                <td rowspan="1" colspan="1">M2REMAP(base)</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.912</td>
                <td rowspan="1" colspan="1">0.897</td>
                <td rowspan="1" colspan="1">0.858 (@3)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">M2REMAP</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.987</td>
                <td rowspan="1" colspan="1">0.985</td>
                <td rowspan="1" colspan="1">0.975 (@3)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">SIDER-FAERS (cross-year)</td>
                <td rowspan="1" colspan="1">M2REMAP(base)</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.835</td>
                <td rowspan="1" colspan="1">0.776</td>
                <td rowspan="1" colspan="1">0.597 (@3)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">M2REMAP</td>
                <td rowspan="1" colspan="1">Chemical</td>
                <td rowspan="1" colspan="1">0.912</td>
                <td rowspan="1" colspan="1">0.907</td>
                <td rowspan="1" colspan="1">0.859 (@3)</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
    </sec>
    <sec>
      <title>3.4 Case studies of novel predictions</title>
      <p>We conduct case studies to examine M2REMAP’s novel molecule–disease predictions. First, we study the molecules predicted to be therapeutic to cancers. Then, we predict potential molecules for COVID-19, a novel disease, considering available treatment information. Finally, we examine side-effect predictions of drugs recently withdrawn due to severe adverse events.</p>
      <sec>
        <title>3.4.1 Cancer-therapeutic molecules</title>
        <p>We first examine the Drugbank (<xref rid="btad085-B39" ref-type="bibr">Wishart <italic toggle="yes">et al.</italic>, 2018</xref>) molecules that M2REMAP predicts to be potentially therapeutic to cancers. We rank the molecules based on cumulative confidence, which sums up the probability of cancer-related indications among their top 50 predictions. Among the top 20 molecules, we can find 9 with literature supports as shown in <xref rid="btad085-T5" ref-type="table">Table 5</xref>, which provides each molecule with the top two cancer-related predictions. The investigational DB03701 (Vanoxerine), which is semantically close to liver-related diseases as shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S2b</xref>, is predicted with indications of ‘liver cell carcinoma (C2239176)’. This is supported by <xref rid="btad085-B50" ref-type="bibr">Zhu <italic toggle="yes">et al.</italic> (2021)</xref>, which has shown its therapeutic effect on hepatocellular carcinoma. The DB14184 (Cinnamaldehyde), in an experimental stage, is predicted to treat ‘malignant tumor of breast’, which is supported by <xref rid="btad085-B6" ref-type="bibr">Chiang <italic toggle="yes">et al.</italic> (2019)</xref> and <xref rid="btad085-B25" ref-type="bibr">Liu <italic toggle="yes">et al.</italic> (2020)</xref>. There are also two approved drugs. DB00715 (Paroxetine), which is predicted to treat ‘malignant tumor of breast’, is a type of antidepressant and labeled with psychotropic indications including ‘major depressive disorder’, ‘obsessive-compulsive disorder’, etc. Some recent studies have revealed its anti-cancer effects, for example, breast cancer in <xref rid="btad085-B7" ref-type="bibr">Cho <italic toggle="yes">et al.</italic> (2019)</xref> and colon cancer in <xref rid="btad085-B20" ref-type="bibr">Jang <italic toggle="yes">et al.</italic> (2019)</xref>. DB02701 (Nicotinamide) is a water-soluble vitamin B3 or niacin and is labeled with indications of ‘acne vulgaris’, ‘pellagra’ and ‘niacin deficiency’. M2REMAP predicts it with indications of ‘neoplasm of prostate (C0033578)’ and ‘malignant tumor of the cervix (C0007847)’. The effectiveness of the drug as cancer chemoprevention and therapy is supported by <xref rid="btad085-B29" ref-type="bibr">Nikas <italic toggle="yes">et al.</italic> (2020)</xref> and <xref rid="btad085-B33" ref-type="bibr">Scatozza <italic toggle="yes">et al.</italic> (2020)</xref>.</p>
        <table-wrap position="float" id="btad085-T5">
          <label>Table 5.</label>
          <caption>
            <p>Literature validation of Drugbank molecules predicted to be therapeutic to cancers</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1">Molecule</th>
                <th rowspan="1" colspan="1">M2REMAP prediction</th>
                <th rowspan="1" colspan="1">Stage</th>
                <th rowspan="1" colspan="1">Evidence</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">DB14980(AZD-6482)</td>
                <td rowspan="1" colspan="1">Malignant lymphoma, glioblastoma multiforme</td>
                <td rowspan="1" colspan="1">Investigational</td>
                <td rowspan="1" colspan="1">Anti-proliferation (<xref rid="btad085-B47" ref-type="bibr">Zhao <italic toggle="yes">et al.</italic>, 2021</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB14017(H3B-8800)</td>
                <td rowspan="1" colspan="1">Hairy cell leukemia, acute myeloid leukemia</td>
                <td rowspan="1" colspan="1">Investigational</td>
                <td rowspan="1" colspan="1">Antitumor (<xref rid="btad085-B34" ref-type="bibr">Seiler <italic toggle="yes">et al.</italic>, 2018</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB15190(GLPG-0259)</td>
                <td rowspan="1" colspan="1">Non-small cell lung cancer, metastatic malignant melanoma</td>
                <td rowspan="1" colspan="1">Investigational</td>
                <td rowspan="1" colspan="1">Tumor metastasis (<xref rid="btad085-B38" ref-type="bibr">Wang <italic toggle="yes">et al.</italic>, 2021</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB03701(Vanoxerine)</td>
                <td rowspan="1" colspan="1">Medullary thyroid carcinoma, liver cell carcinoma</td>
                <td rowspan="1" colspan="1">Investigational</td>
                <td rowspan="1" colspan="1">Hepatocellular carcinoma (<xref rid="btad085-B50" ref-type="bibr">Zhu <italic toggle="yes">et al.</italic>, 2021</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB06266(Lonidamine)</td>
                <td rowspan="1" colspan="1">Malignant tumor of breast, medullary thyroid carcinoma</td>
                <td rowspan="1" colspan="1">Investigational</td>
                <td rowspan="1" colspan="1">Antitumour (<xref rid="btad085-B18" ref-type="bibr">Huang <italic toggle="yes">et al.</italic>, 2020</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB11455(Robenacoxib)</td>
                <td rowspan="1" colspan="1">Hairy cell leukemia, malignant tumor of breast</td>
                <td rowspan="1" colspan="1">Experimental</td>
                <td rowspan="1" colspan="1">antitumour (<xref rid="btad085-B29" ref-type="bibr">Nikas <italic toggle="yes">et al.</italic>, 2020</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB14184(Cinnamaldehyde)</td>
                <td rowspan="1" colspan="1">Malignant tumor of breast, metastatic malignant melanoma</td>
                <td rowspan="1" colspan="1">Experimental</td>
                <td rowspan="1" colspan="1">Breast cancer (<xref rid="btad085-B25" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2020</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB00715(Paroxetine)</td>
                <td rowspan="1" colspan="1">Malignant tumor of breast, gestational trophoblastic neoplasia</td>
                <td rowspan="1" colspan="1">Approved</td>
                <td rowspan="1" colspan="1">Anticancer activity (<xref rid="btad085-B7" ref-type="bibr">Cho <italic toggle="yes">et al.</italic>, 2019</xref>)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB02701(Nicotinamide)</td>
                <td rowspan="1" colspan="1">Neoplasm of prostate, malignant tumor of cervix</td>
                <td rowspan="1" colspan="1">Approved</td>
                <td rowspan="1" colspan="1">Cancer therapy (<xref rid="btad085-B32" ref-type="bibr">Sauer <italic toggle="yes">et al.</italic>, 2021</xref>)</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec>
        <title>3.4.2 Molecules for COVID-19</title>
        <p>We next study the generalization of M2REMAP in predicting therapeutic molecules for COVID-19 as a novel disease. To this end, we first train an embedding vector for COVID-19, which is represented by the EHR concept of ‘COVID-19 PCR test positive’, based on the skip-gram algorithm using the co-occurrence matrix of EHR concepts assembled for VA patients with a COVID-19 diagnostic code between March 2020 and September 2021. This allows us to create a new set of embeddings for 5272 EHR concepts, including COVID-19, and a subset of 2105 diagnosis codes shared with the existing VA EHR concepts. To map the COVID-19 embedding to the VA embedding space, we train a neural network in a supervised manner to learn the mapping from the new embeddings with COVID-19 to the previously trained VA embedding. Therein, we obtain the VA embedding vector of COVID-19. The detailed learning procedures are provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Note S2</xref>. With the newly trained COVID-19 embedding and the relation predictor, we identify the top Drugbank molecules with a high likelihood of having COVID-19 as their indications. We rank the molecules by the prediction scores given by M2REMAP. In addition, as described in Section 3.1, molecules tend to be close to the corresponding target indications. Therefore, we refine the prediction results by removing the molecules with a cosine similarity of &lt;0.1 to COVID-19.</p>
        <p>The results are provided in <xref rid="btad085-T6" ref-type="table">Table 6</xref>. Among the top 20 predictions by M2REMAP, which are visualized in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S2</xref>, seven molecules are found with literature evidence. M2REMAP successfully predicts DB14761 (Remdesivir), which FDA approved to treat COVID-19. The top candidate predicted by M2REMAP is DB00481 (Raloxifene), a selective estrogen receptor modulator for the treatment and prevention of postmenopausal osteoporosis and cancer, which is recently shown to potentially treat SARS-CoV-2 infection in <xref rid="btad085-B17" ref-type="bibr">Hong <italic toggle="yes">et al.</italic> (2021b)</xref> and <xref rid="btad085-B1" ref-type="bibr">Allegretti <italic toggle="yes">et al.</italic> (2022)</xref>. The DB01268 (Sunitinib), a kinase inhibitor, is also of great potential as an anti-coronavirus drug, as shown in <xref rid="btad085-B37" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> (2020)</xref>. Three molecules are still not marketed. Specifically, DB13527 (Proglumetacin), at an experimental stage, is shown to inhibit SARS-CoV-2 in <xref rid="btad085-B2" ref-type="bibr">Alves <italic toggle="yes">et al.</italic> (2021)</xref>, DB12181 (Dalcetrapib), at an investigational stage, is shown to have inhibitory effects on the SARS-CoV-2 3CL protease and viral replication (<xref rid="btad085-B28" ref-type="bibr">Niesor <italic toggle="yes">et al.</italic>, 2021</xref>), and DB05420 (Gallium maltolate), at an investigational stage, is shown to inhibit the replication of SARS-CoV-2 (<xref rid="btad085-B4" ref-type="bibr">Bernstein and Zhang, 2020</xref>).</p>
        <table-wrap position="float" id="btad085-T6">
          <label>Table 6.</label>
          <caption>
            <p>Drugbank molecules predicted to be therapeutic to COVID-19</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="char" char="." span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1">Molecule</th>
                <th rowspan="1" colspan="1">Ranking</th>
                <th rowspan="1" colspan="1">Stage</th>
                <th rowspan="1" colspan="1">Evidence</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">DB14761(Remdesivir)</td>
                <td rowspan="1" colspan="1">17</td>
                <td rowspan="1" colspan="1">Approved; investigational</td>
                <td rowspan="1" colspan="1">Approved for COVID-19</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB00481(Raloxifene)</td>
                <td rowspan="1" colspan="1">1</td>
                <td rowspan="1" colspan="1">Approved; investigational</td>
                <td rowspan="1" colspan="1">
                  <xref rid="btad085-B17" ref-type="bibr">Hong <italic toggle="yes">et al.</italic> (2021b)</xref>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB01268(Sunitinib)</td>
                <td rowspan="1" colspan="1">3</td>
                <td rowspan="1" colspan="1">Approved; investigational</td>
                <td rowspan="1" colspan="1">
                  <xref rid="btad085-B37" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> (2020)</xref>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB05420(Gallium maltolate)</td>
                <td rowspan="1" colspan="1">5</td>
                <td rowspan="1" colspan="1">Investigational</td>
                <td rowspan="1" colspan="1">
                  <xref rid="btad085-B4" ref-type="bibr">Bernstein and Zhang (2020)</xref>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB13527(Proglumetacin)</td>
                <td rowspan="1" colspan="1">6</td>
                <td rowspan="1" colspan="1">Experimental</td>
                <td rowspan="1" colspan="1">
                  <xref rid="btad085-B2" ref-type="bibr">Alves <italic toggle="yes">et al.</italic> (2021)</xref>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB12181(Dalcetrapib)</td>
                <td rowspan="1" colspan="1">13</td>
                <td rowspan="1" colspan="1">Investigational</td>
                <td rowspan="1" colspan="1">
                  <xref rid="btad085-B28" ref-type="bibr">Niesor <italic toggle="yes">et al.</italic> (2021)</xref>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB11753(Rifamycin)</td>
                <td rowspan="1" colspan="1">14</td>
                <td rowspan="1" colspan="1">Approved; investigational</td>
                <td rowspan="1" colspan="1">
                  <xref rid="btad085-B30" ref-type="bibr">Pathak <italic toggle="yes">et al.</italic> (2021)</xref>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec>
        <title>3.4.3 Drug withdrawal prediction</title>
        <p>We examine the side effect predictions of the 12 drugs withdrawn from the market because of severe adverse effects (<ext-link xlink:href="https://en.wikipedia.org/wiki/List_of_withdrawn_drugs" ext-link-type="uri">https://en.wikipedia.org/wiki/List_of_withdrawn_drugs</ext-link>) since 2008. We train M2REMAP on the SIDER 4.1 (<xref rid="btad085-B21" ref-type="bibr">Kuhn <italic toggle="yes">et al.</italic>, 2016</xref>). As shown in <xref rid="btad085-T7" ref-type="table">Table 7</xref>, the results are in three parts. In the first part, four drugs are not included in SIDER 4.1 and thus are considered novel molecules. M2REMAP correctly predicts the leading causes of withdrawal. The second part in <xref rid="btad085-T7" ref-type="table">Table 7</xref> contains three drugs included in SIDER 4.1, but no side effects related to the withdrawal are reported. The three drugs, Lorcaserin, Ranitidine and Ingenol mebutate, are withdrawn because of the increased risk of cancers, which aligns with M2REMAP predictions. For those seven drugs without withdrawal-related side effects reported on the SIDER 4.1, M2REMAP achieves a recall<inline-formula id="IE33"><mml:math id="IM33" display="inline" overflow="scroll"><mml:mo>@</mml:mo></mml:math></inline-formula>50 of 1.0, significantly better than a random guess of 0.141. The third part in <xref rid="btad085-T7" ref-type="table">Table 7</xref> consists of five drugs with related side effects reported in SIDER 4.1, and M2REMAP also successfully specifies the withdrawal causes.</p>
        <table-wrap position="float" id="btad085-T7">
          <label>Table 7.</label>
          <caption>
            <p>Side-effect predictions of drugs recently withdrawn due to adverse events</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1">Drugbank ID</th>
                <th rowspan="1" colspan="1">M2REMAP prediction</th>
                <th rowspan="1" colspan="1">Regions withdrawn</th>
                <th rowspan="1" colspan="1">Reason for withdrawal</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">DB06623(Flupirtine)</td>
                <td rowspan="1" colspan="1">Cholangitis, hepatotoxicity</td>
                <td rowspan="1" colspan="1">EU, 2018</td>
                <td rowspan="1" colspan="1">Liver injury</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB13324(Tetrazepam)</td>
                <td rowspan="1" colspan="1">Lip ulceration, localized erythema</td>
                <td rowspan="1" colspan="1">EU, 2013</td>
                <td rowspan="1" colspan="1">Serious cutaneous reactions</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB01283(Lumiracoxib)</td>
                <td rowspan="1" colspan="1">Jaundice hepatocellular, hepatocellular injury</td>
                <td rowspan="1" colspan="1">Worldwide, 2008</td>
                <td rowspan="1" colspan="1">Liver damage</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB09004(Clobutinol)</td>
                <td rowspan="1" colspan="1">Bradyarrhythmia, atrial rhythm</td>
                <td rowspan="1" colspan="1">Worldwide, 2008</td>
                <td rowspan="1" colspan="1">Ventricular arrhythmia</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB04871(Lorcaserin)</td>
                <td rowspan="1" colspan="1">Carcinoma testes, breast cancer</td>
                <td rowspan="1" colspan="1">US, 2020</td>
                <td rowspan="1" colspan="1">Risk of cancer</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB00863(Ranitidine)</td>
                <td rowspan="1" colspan="1">Carcinoma of prostate, brain neoplasm</td>
                <td rowspan="1" colspan="1">US, 2020</td>
                <td rowspan="1" colspan="1">Risk of cancer</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB05013(Ingenol mebutate)</td>
                <td rowspan="1" colspan="1">Malignant melanoma, depigmentation</td>
                <td rowspan="1" colspan="1">EU, 2020</td>
                <td rowspan="1" colspan="1">Risk of skin cancers</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB06268(Sitaxentan)</td>
                <td rowspan="1" colspan="1">Jaundice hepatocellular</td>
                <td rowspan="1" colspan="1">Germany, 2010</td>
                <td rowspan="1" colspan="1">Hepatotoxicity</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB01105(Sibutramine)</td>
                <td rowspan="1" colspan="1">Bradyarrhythmia, coronary heart disease,</td>
                <td rowspan="1" colspan="1">US, 2010</td>
                <td rowspan="1" colspan="1">Cardiovascular events</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB00647(Dextropropoxyphene)</td>
                <td rowspan="1" colspan="1">Atrial rhythm, sinus arrest</td>
                <td rowspan="1" colspan="1">Worldwide, 2010</td>
                <td rowspan="1" colspan="1">Heart attacks and stroke</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB00412(Rosiglitazone)</td>
                <td rowspan="1" colspan="1">Hypernatraemia, sinus arrest</td>
                <td rowspan="1" colspan="1">EU, 2010</td>
                <td rowspan="1" colspan="1">Heart attacks and death</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DB06155(Rimonabant)</td>
                <td rowspan="1" colspan="1">Dependence psychological, depressive disorder</td>
                <td rowspan="1" colspan="1">Worldwide, 2008</td>
                <td rowspan="1" colspan="1">Depressive disorders</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
    </sec>
  </sec>
  <sec>
    <title>4 Discussions</title>
    <p>M2REMAP attains higher accuracy and generalizability for predicting molecule–disease relations over existing methods by effectively combining chemical structure, and semantic representations of clinical concepts learned from EHR. By mapping large-scale clinical concepts, including indications, side effects and drug molecules, onto a shared semantic embedding space, M2REMAP bridges the semantic gap between molecule chemicals and clinical concepts. M2REMAP is flexible and relatively robust to the choice of different pipelines for feature extractors. For example, the current implementation of the feature extractor <bold>E</bold> in M2REMAP uses the CNN+bi-GRU architecture, which can potentially be replaced by alternative network architectures such as the Transformer (<xref rid="btad085-B36" ref-type="bibr">Vaswani <italic toggle="yes">et al.</italic>, 2017</xref>) with molecular SMILE as input and MPNN (<xref rid="btad085-B12" ref-type="bibr">Gilmer <italic toggle="yes">et al.</italic>, 2017</xref>) with molecular graphs as input. As shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Note S1</xref>, M2REMAP with different network architectures has comparable performances although CNN+bi-GRU appears to be the most robust.</p>
    <p>When integrating EHR embedding information with chemical structures and existing labels on side effects and indications, it is critical to leverage both structured and textual EHR data extracted via NLP, especially for studying side effects. Drug side effects are often symptoms that cannot be well captured by diagnostic codes but can be well represented by UMLS CUIs that cover a broader range of semantic types, including disease, symptoms, clinical attributes and findings. In addition, even for side effects that can be mapped to diagnostic codes, physicians may record the side effects information in clinical notes but only assign diagnostic codes associated with the disease the patient is treated for.</p>
    <p>As demonstrated by the COVID-19 case study, M2REMAP enables predictions of therapeutic molecules for novel diseases by leveraging EHR as a live system to learn semantic representation for novel diseases. This is a key advantage of M2REMAP over existing methods which typically require the diseases to be pre-defined with annotated drug–disease relations. Furthermore, there is currently no effective strategy to represent novel diseases when limited knowledge exists. Neither one-hot encoding nor text description can fully capture the clinical characteristics of a novel disease. On the other hand, results from the COVID-19 case study suggest that the co-occurrence patterns of EHR concepts can effectively train embeddings to represent novel diseases, which can then be integrated into the M2REMAP pipeline for the prediction of indications.</p>
    <p>There are several directions for future study. First, by linking with all EHR concepts, the semantic embedding can also be used to infer the relationship between molecules and other clinical concepts, for example, laboratory and therapeutic procedures, and improve molecule-related research such as predicting molecule properties, target proteins, etc. The current implementation of M2REMAP achieved robust performance by combining information from chemical structure and clinical information from EHR. However, we expect that M2REMAP can be modified to gain higher accuracy by further leveraging molecule biological properties such as target proteins, enzymes, pathways, etc., which are available for a subset of molecules via semi-supervised learning.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btad085_Supplementary_Data</label>
      <media xlink:href="btad085_supplementary_data.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec>
    <title>Author contributions</title>
    <p>Conceptualization: T.C. and M.Z.; Methodology: J.W., X.Z., T.C. and M.Z.; Data processing and analysis: J.W., X.Z., X.L., V.P., E.R., Y.H. and L.C.; Project administration: K.C.; Writing: J.W., T.C., M.Z., X.Z, X.L, V.P, E.R, K.P.L, J.L. and D.Z.; Guarantors: T.C. and M.Z.; Approval of final manuscript: all authors.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>Part of this research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration and was supported by award [#MVP000]. KPL is supported by the NIH P30 AR072577. This publication does not represent the views of the Department of Veteran Affairs or the United States Government.</p>
    <p><italic toggle="yes">Conflict of Interest</italic>: None declared.</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>The data underlying this article are available in the article and in its online <xref rid="sup1" ref-type="supplementary-material">supplementary material</xref>.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btad085-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Allegretti</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2022</year>) <article-title>Repurposing the estrogen receptor modulator raloxifene to treat SARS-COV-2 infection</article-title>. <source>Cell Death Differ</source>., <volume>29</volume>, <fpage>156</fpage>–<lpage>166</lpage>.<pub-id pub-id-type="pmid">34404919</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alves</surname><given-names>V.M.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>QSAR modeling of SARS-CoV M<sup>pro</sup> inhibitors identifies sufugolix, cenicriviroc, proglumetacin, and other drugs as candidates for repurposing against SARS-CoV-2</article-title>. <source>Mol. Inf</source>., <volume>40</volume>, <fpage>2000113</fpage>.</mixed-citation>
    </ref>
    <ref id="btad085-B3">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Beam</surname><given-names>A.L.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) Clinical concept embeddings learned from massive sources of multimodal medical data. In: <italic toggle="yes">Pacific Symposium on Biocomputing 2020</italic>, <italic toggle="yes">Hawaii</italic>, pp. <fpage>295</fpage>–<lpage>306</lpage>. World Scientific.</mixed-citation>
    </ref>
    <ref id="btad085-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bernstein</surname><given-names>L.R.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Gallium maltolate has in vitro antiviral activity against SARS-CoV-2 and is a potential treatment for COVID-19</article-title>. <source>Antivir. Chem. Chemother</source>., <volume>28</volume>, <fpage>2040206620983780</fpage>.<pub-id pub-id-type="pmid">33353394</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B5">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Chandak</surname><given-names>P.</given-names></string-name></person-group><etal>et al</etal> (<year>2022</year>) Building a knowledge graph to enable precision medicine. <italic toggle="yes">Scientific Data</italic>, <bold>10</bold>(1), 67.</mixed-citation>
    </ref>
    <ref id="btad085-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chiang</surname><given-names>Y.-F.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Dietary antioxidant trans-cinnamaldehyde reduced visfatin-induced breast cancer progression: in vivo and in vitro study</article-title>. <source>Antioxidants</source>, <volume>8</volume>, <fpage>625</fpage>.<pub-id pub-id-type="pmid">31817697</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cho</surname><given-names>Y.-W.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Paroxetine induces apoptosis of human breast cancer MCF-7 cells through Ca2+-and p38 MAP kinase-dependent ROS generation</article-title>. <source>Cancers</source>, <volume>11</volume>, <fpage>64</fpage>.<pub-id pub-id-type="pmid">30634506</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DiMasi</surname><given-names>J.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) <article-title>Innovation in the pharmaceutical industry: new estimates of R&amp;D costs</article-title>. <source>J. Health Econ</source>., <volume>47</volume>, <fpage>20</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">26928437</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Edwards</surname><given-names>J.E.</given-names></string-name></person-group><etal>et al</etal> (<year>1999</year>) <article-title>Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain</article-title>. <source>J. Pain Symptom Manage</source>., <volume>18</volume>, <fpage>427</fpage>–<lpage>437</lpage>.<pub-id pub-id-type="pmid">10641469</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fioravanti</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) <article-title>A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline</article-title>. <source>BMJ Open</source>, <volume>4</volume>, <fpage>e005090</fpage>.</mixed-citation>
    </ref>
    <ref id="btad085-B12">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Gilmer</surname><given-names>J.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) Neural message passing for quantum chemistry. In: <italic toggle="yes">International Conference on Machine Learning</italic>, <italic toggle="yes">Sydney</italic>, pp. <fpage>1263</fpage>–<lpage>1272</lpage>. PMLR.</mixed-citation>
    </ref>
    <ref id="btad085-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Golder</surname><given-names>S.</given-names></string-name></person-group><etal>et al</etal> (<year>2011</year>) <article-title>Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview</article-title>. <source>PLoS Med</source>., <volume>8</volume>, <fpage>e1001026</fpage>.<pub-id pub-id-type="pmid">21559325</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gómez-Bombarelli</surname><given-names>R.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>Automatic chemical design using a data-driven continuous representation of molecules</article-title>. <source>ACS Cent. Sci</source>., <volume>4</volume>, <fpage>268</fpage>–<lpage>276</lpage>.<pub-id pub-id-type="pmid">29532027</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B15">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Grover</surname><given-names>A.</given-names></string-name>, <string-name><surname>Leskovec</surname><given-names>J.</given-names></string-name></person-group> (<year>2016</year>) node2vec: scalable feature learning for networks. In: <italic toggle="yes">Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge discOvery and DATA mining</italic>, <italic toggle="yes">San Francisco</italic>, pp. <fpage>855</fpage>–<lpage>864</lpage>.</mixed-citation>
    </ref>
    <ref id="btad085-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hong</surname><given-names>C.</given-names></string-name></person-group><etal>et al</etal> (<year>2021a</year>) <article-title>Clinical knowledge extraction via sparse embedding regression (KESER) with multi-center large scale electronic health record data</article-title>. <source>NPJ Digit. Med</source>., <bold>4</bold>(1), 151.</mixed-citation>
    </ref>
    <ref id="btad085-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hong</surname><given-names>S.</given-names></string-name></person-group><etal>et al</etal> (<year>2021b</year>) <article-title>Raloxifene as a treatment option for viral infections</article-title>. <source>J. Microbiol</source>., <volume>59</volume>, <fpage>124</fpage>–<lpage>131</lpage>.<pub-id pub-id-type="pmid">33527314</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>Y.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>The potential of lonidamine in combination with chemotherapy and physical therapy in cancer treatment</article-title>. <source>Cancers</source>, <volume>12</volume>, <fpage>3332</fpage>.<pub-id pub-id-type="pmid">33187214</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jamal</surname><given-names>S.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>Predicting neurological adverse drug reactions based on biological, chemical and phenotypic properties of drugs using machine learning models</article-title>. <source>Sci. Rep</source>., <volume>7</volume>, <fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">28127051</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jang</surname><given-names>W.-J.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Anticancer activity of paroxetine in human colon cancer cells: involvement of MET and ERBB3</article-title>. <source>J. Cell. Mol. Med</source>., <volume>23</volume>, <fpage>1106</fpage>–<lpage>1115</lpage>.<pub-id pub-id-type="pmid">30421568</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuhn</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) <article-title>The sider database of drugs and side effects</article-title>. <source>Nucleic Acids Res</source>., <volume>44</volume>, <fpage>D1075</fpage>–<lpage>D1079</lpage>.<pub-id pub-id-type="pmid">26481350</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.-P.P.</given-names></string-name></person-group> (<year>2021</year>) <article-title>Prediction of drug adverse events using deep learning in pharmaceutical discovery</article-title>. <source>Brief. Bioinform</source>., <volume>22</volume>, <fpage>1884</fpage>–<lpage>1901</lpage>.<pub-id pub-id-type="pmid">32349125</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Levy</surname><given-names>O.</given-names></string-name>, <string-name><surname>Goldberg</surname><given-names>Y.</given-names></string-name></person-group> (<year>2014</year>) Neural word embedding as implicit matrix factorization. In: Advances in Neural Information Processing Systems, <italic toggle="yes">Montreal</italic>, Vol. <volume>27</volume>.</mixed-citation>
    </ref>
    <ref id="btad085-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2012</year>) <article-title>Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs</article-title>. <source>J. Am. Med. Inform. Assoc</source>., <volume>19</volume>, <fpage>e28</fpage>–<lpage>e35</lpage>.<pub-id pub-id-type="pmid">22718037</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Y.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>Targets and mechanism used by cinnamaldehyde, the main active ingredient in cinnamon, in the treatment of breast cancer</article-title>. <source>Front. Pharmacol</source>., <volume>11</volume>, <fpage>1751</fpage>.</mixed-citation>
    </ref>
    <ref id="btad085-B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohs</surname><given-names>R.C.</given-names></string-name>, <string-name><surname>Greig</surname><given-names>N.H.</given-names></string-name></person-group> (<year>2017</year>) <article-title>Drug discovery and development: role of basic biological research</article-title>. <source>Alzheimers Dement (NY)</source>, <volume>3</volume>, <fpage>651</fpage>–<lpage>657</lpage>.</mixed-citation>
    </ref>
    <ref id="btad085-B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muñoz</surname><given-names>E.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Facilitating prediction of adverse drug reactions by using knowledge graphs and multi-label learning models</article-title>. <source>Brief. Bioinform</source>., <volume>20</volume>, <fpage>190</fpage>–<lpage>202</lpage>.<pub-id pub-id-type="pmid">28968655</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Niesor</surname><given-names>E.J.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>Inhibition of the 3cl protease and sars-cov-2 replication by dalcetrapib</article-title>. <source>ACS Omega</source>, <volume>6</volume>, <fpage>16584</fpage>–<lpage>16591</lpage>.<pub-id pub-id-type="pmid">34235330</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nikas</surname><given-names>I.P.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>The role of nicotinamide in cancer chemoprevention and therapy</article-title>. <source>Biomolecules</source>, <volume>10</volume>, <fpage>477</fpage>.<pub-id pub-id-type="pmid">32245130</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pathak</surname><given-names>Y.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>Rifampicin and letermovir as potential repurposed drug candidate for covid-19 treatment: insights from an in-silico study</article-title>. <source>Pharmacol. Rep</source>., <volume>73</volume>, <fpage>926</fpage>–<lpage>938</lpage>.<pub-id pub-id-type="pmid">33970450</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rogers</surname><given-names>D.</given-names></string-name>, <string-name><surname>Hahn</surname><given-names>M.</given-names></string-name></person-group> (<year>2010</year>) <article-title>Extended-connectivity fingerprints</article-title>. <source>J. Chem. Inf. Model</source>., <volume>50</volume>, <fpage>742</fpage>–<lpage>754</lpage>.<pub-id pub-id-type="pmid">20426451</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sauer</surname><given-names>H.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>The nicotinamide phosphoribosyltransferase antagonist fk866 inhibits growth of prostate tumour spheroids and increases doxorubicin retention without changes in drug transporter and cancer stem cell protein expression</article-title>. <source>Clin. Exp. Pharmacol. Physiol</source>., <volume>48</volume>, <fpage>422</fpage>–<lpage>434</lpage>.<pub-id pub-id-type="pmid">33349973</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scatozza</surname><given-names>F.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>Nicotinamide inhibits melanoma in vitro and in vivo</article-title>. <source>J. Exp. Clin. Cancer Res</source>., <volume>39</volume>, <fpage>1</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">31928527</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seiler</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>H3b-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers</article-title>. <source>Nat. Med</source>., <volume>24</volume>, <fpage>497</fpage>–<lpage>504</lpage>.<pub-id pub-id-type="pmid">29457796</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Van der Maaten</surname><given-names>L.</given-names></string-name>, <string-name><surname>Hinton</surname><given-names>G.</given-names></string-name></person-group> (<year>2008</year>) <article-title>Visualizing data using t-SNE</article-title>. <source>J. Mach. Learn. Res</source>., <volume>9</volume>(<issue>11</issue>), <fpage>2579</fpage>–<lpage>2605</lpage>.</mixed-citation>
    </ref>
    <ref id="btad085-B36">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Vaswani</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) Attention is all you need. In: Advances in Neural Information Processing Systems, <italic toggle="yes">Long Beach</italic>, Vol. 30.</mixed-citation>
    </ref>
    <ref id="btad085-B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>P.-G.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation</article-title>. <source>Cell Discov</source>., <volume>6</volume>, <fpage>1</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">31934347</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>The essential role of PRAK in tumor metastasis and its therapeutic potential</article-title>. <source>Nat. Commun</source>., <volume>12</volume>, <fpage>1</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">33397941</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B39">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res</source>., <volume>46</volume>, <fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B40">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamanishi</surname><given-names>Y.</given-names></string-name></person-group><etal>et al</etal> (<year>2012</year>) <article-title>Drug side-effect prediction based on the integration of chemical and biological spaces</article-title>. <source>J. Chem. Inf. Model</source>., <volume>52</volume>, <fpage>3284</fpage>–<lpage>3292</lpage>.<pub-id pub-id-type="pmid">23157436</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B41">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Yu</surname><given-names>S.</given-names></string-name></person-group><etal>et al</etal> (<year>2013</year>) Nile: fast natural language processing for electronic health records. arXiv, arXiv:1311.6063, preprint: not peer reviewed.</mixed-citation>
    </ref>
    <ref id="btad085-B42">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname><given-names>Y.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>SumGNN: multi-typed drug interaction prediction via efficient knowledge graph summarization</article-title>. <source>Bioinformatics</source>, <volume>37</volume>, <fpage>2988</fpage>–<lpage>2995</lpage>.<pub-id pub-id-type="pmid">33769494</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B43">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zagidullin</surname><given-names>B.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>Comparative analysis of molecular fingerprints in prediction of drug combination effects</article-title>. <source>Brief. Bioinformatics</source>, <volume>22</volume>, <fpage>bbab291</fpage>.<pub-id pub-id-type="pmid">34401895</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B44">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>W.</given-names></string-name></person-group><etal>et al</etal> (<year>2015</year>) <article-title>Predicting drug side effects by multi-label learning and ensemble learning</article-title>. <source>BMC Bioinformatics</source>, <volume>16</volume>, <fpage>1</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">25591917</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B45">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>W.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) Drug side effect prediction through linear neighborhoods and multiple data source integration. In: <italic toggle="yes">2016 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)</italic>, <italic toggle="yes">Shenzhen</italic>, pp. <fpage>427</fpage>–<lpage>434</lpage>. IEEE.</mixed-citation>
    </ref>
    <ref id="btad085-B46">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>X.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>Population-scale identification of differential adverse events before and during a pandemic</article-title>. <source>Nat. Comput. Sci</source>., <volume>1</volume>, <fpage>666</fpage>–<lpage>677</lpage>.</mixed-citation>
    </ref>
    <ref id="btad085-B47">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>H.-f.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>Synergism between the phosphatidylinositol 3-kinase p110<italic toggle="yes">β</italic> isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation</article-title>. <source>Cancer Cell Int</source>., <volume>21</volume>, <fpage>1</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">33397383</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B48">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname><given-names>Y.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Inverse similarity and reliable negative samples for drug side-effect prediction</article-title>. <source>BMC Bioinformatics</source>, <volume>19</volume>, <fpage>91</fpage>–<lpage>104</lpage>.</mixed-citation>
    </ref>
    <ref id="btad085-B49">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>H.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>MEDICASCY: a machine learning approach for predicting small-molecule drug side effects, indications, efficacy, and modes of action</article-title>. <source>Mol. Pharm</source>., <volume>17</volume>, <fpage>1558</fpage>–<lpage>1574</lpage>.<pub-id pub-id-type="pmid">32237745</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B50">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>Y.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma</article-title>. <source>Mol. Med</source>., <volume>27</volume>, <fpage>1</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">33402118</pub-id></mixed-citation>
    </ref>
    <ref id="btad085-B51">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zitnik</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>Modeling polypharmacy side effects with graph convolutional networks</article-title>. <source>Bioinformatics</source>, <volume>34</volume>, <fpage>i457</fpage>–<lpage>i466</lpage>.<pub-id pub-id-type="pmid">29949996</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
